Prostate Cancer Program

前列腺癌的治疗方法 前列腺癌（PR）计划的使命是降低与前列腺癌相关的发病率和死亡率。 前列腺癌通过在生物学，临床和人群水平上对疾病的深入了解。 该计划通过跨学科的研究来实现这一使命， 翻译自上一次竞争性续约以来，战略规划流程促成了三个 新的跨学科主题： 主题1：发现前列腺癌的生物和分子驱动因素 主题2：生物标志物和预后模型开发，以预测男性前列腺癌患者的结局 主题3：开发治疗干预措施以改善男性前列腺癌患者的结局 公关计划：关键的 成员（10个系，1所学校）37 整整24 协理13 与癌症有关的供资（截至2009年的直接费用） 13 878 515美元 2017年05月31日） NCI $5，543，247 40% 同行评审$5，289，510 38% 非同行评审3，045，758美元22% 癌症相关出版物（1/2012-7/2017）616 方案间 方案内 高影响力198 32% 临床试验应计费用（2016年）923 46 治疗. 99 20 其他干预措施416 12 非干预性408 14

Prostate Cancer Program: Summary The mission of the Prostate Cancer (PR) Program is to reduce the morbidity and mortality associated with Prostate Cancer by leveraging a deep understanding of the disease at a biologic, clinical, and population level. The Program approaches this mission with transdisciplinary research that is richly collaborative and translational. Since the last competitive renewal, a strategic planning process led to the development of three new transdisciplinary themes: Theme 1: Discovery of Biologic and Molecular Drivers of Prostate Cancer Theme 2: Biomarker and Prognostic Model Development to Predict Outcomes in Men with Prostate Cancer Theme 3: Developing Therapeutic Interventions to Improve Outcomes for Men with Prostate Cancer PR Program: Key Metrics Membership (10 departments, 1 school) 37 Full 24 Associate 13 Cancer-relevant Funding (direct costs as of $13,878,515 05/31/2017) NCI $5,543,247 40% Peer-reviewed $5,289,510 38% Non-peer-reviewed $3,045,758 22% Cancer-relevant Publications (1/2012-7/2017) 616 Inter-programmatic 160 26% Intra-Programmatic 257 42% High-Impact 198 32% Accruals to Clinical Trials (2016) 923 46 Therapeutic 99 20 Other Interventional 416 12 Non-interventional 408 14